COG ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Principal Investigator
Photograph of Margaret Macy,  MD

Margaret Macy, MD

Study ID

Protocol Number: 18-0971

More information available at ClinicalTrials.gov: NCT03126916

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers